BNP/CALL/NOVO-NORDISK B/850/0.1/20.09.24 | Market Closed - Boerse Frankfurt Warrants 07:51:04 28/06/2024 pm IST | ||
| 2.35 EUR | +3.98% |
|
| Current month | +57.72% | ||
| 1 month | +72.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 2.35 | +3.98% |
| 27/24/27 | 2.26 | -5.04% |
| 26/24/26 | 2.38 | -3.64% |
| 25/24/25 | 2.47 | +18.75% |
| 24/24/24 | 2.08 | -0.95% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 07:51 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PC25NV |
| ISIN | DE000PC25NV5 |
| Date issued | 10/01/2024 |
| Strike | 850 kr |
| Maturity | 20/09/2024 (82 Days) |
| Parity | 10 : 1 |
| Emission price | 0.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.52 € |
|---|---|
| Lowest since issue | 0.42 € |
| Spread | 0.04 € |
| Spread % | 1.71% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
